Our findings confirm that dual agonism promotes hepatic, metabolic and body weight loss benefits associated with the combined action of glucagon and GLP-1, which could directly underpin the therapeutic effect as a potential treatment for metabolic diseases. Here, GCG is linked to Other metabolic disease.